Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACP-196 in Rheumatoid Arthritis
NCT02387762Phase 2Completed
- Sponsor
- Acerta Pharma
- Start
- Apr 2015
- Primary completion
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in rheumatoid arthritis (RA) comparing ACP-196 + Methotrexate with Placebo + Methotrexate (2 arms). Primary endpoint: Disease Activity Score 28-CRP at 4 weeks. Started Apr 2015; status: completed.
02
Drugs
acalabrutinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02387762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02387762.